FDA Panels Back Abuse-Deterrent Arymo ER for Severe Pain FDA Panels Back Abuse-Deterrent Arymo ER for Severe Pain

Two advisory committees voted 18-1 that the new drug should be approved. They also voted overwhelmingly for labeling it as an abuse deterrent by oral, nasal, and intravenous routes.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news